Compile Data Set for Download or QSAR
Report error Found 1827 of affinity data for UniProtKB/TrEMBL: Q01726
TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323172(US9630949, 1 | US9630949, 3 | N-[(S)-1-[(S)-2-(3-B...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323173(N-[(S)-1-[(S)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-...)
Affinity DataEC50:  30nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323172(US9630949, 1 | US9630949, 3 | N-[(S)-1-[(S)-2-(3-B...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323175(N-[(S)-1-[(S)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323176(1-[(S)-2-[(S)-2-benzoylamino-3-(1H-imidazol-4-yl)p...)
Affinity DataEC50:  4.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323177(1-[(S)-2-[(S)-2-benzoylamino-3-(1H-imidazol-4-yl)p...)
Affinity DataEC50:  2.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323178(N-[(S)-1-[(S)-2-(3-cyclohexyl-3-hydroxyazetidin-1-...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323179(N-[(S)-1-[(S)-2-[3-butoxy-3-(4-fluorophenyl)azetid...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323180(N-[(S)-1-[(S)-2-[3-butoxy-3-(3-fluorophenyl)azetid...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323181(N-[(S)-2-(3-cyclohexyl-3-hydroxyazetidin-1-yl)-1-(...)
Affinity DataEC50:  8.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323182(N-[(S)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)-1-(4-m...)
Affinity DataEC50:  4.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323183(N-[(R)-1-(3,4-dichlorobenzyl)-2-(3-hydroxy-3-pheny...)
Affinity DataEC50:  8.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323184(N-[(S)-2-(3-ethoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  2.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323185(N-[(S)-2-(3-cyclopropylmethoxy-3-o-tolylazetidin-1...)
Affinity DataEC50:  2.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323186(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323187(N-[(S)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  2.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323188(N-[(R)-2-(3-ethoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323189(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-cycloh...)
Affinity DataEC50:  8.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323190(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(2,4-d...)
Affinity DataEC50:  2.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323191(N-[(R)-2-(3-cyclopropylmethoxy-3-o-tolylazetidin-1...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323192(N-[(S)-1-(4-methoxybenzyl)-2-oxo-2-(3-propoxy-3-o-...)
Affinity DataEC50:  4.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323193(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-propoxy-3-o-...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323194(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323195(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyloxy-3-...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323196(N-[(R)-2-(3-hexyloxy-3-o-tolylazetidin-1-yl)-1-(4-...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323197(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-phe...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323198(N-[(R)-2-(3-butyl-3-phenylazetidin-1-yl)-1-(4-meth...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323199(N-[(R)-2-(3-cyclopropylmethoxy-3-phenylazetidin-1-...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323200(N-[(R)-2-(3-hydroxy-3-o-tolylazetidin-1-yl)-1-(4-m...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323201(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323202(N-[(R)-2-[3-butoxy-3-(4-fluorophenyl)azetidin-1-yl...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323203(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(4-flu...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323204(N-{(R)-1-benzyl-2-[3-butoxy-3-(4-fluoro-phenyl)aze...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323205(N-[(R)-1-benzyl-2-(3-butoxy-3-phenylazetidin-1-yl)...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323206(N-[(R)-2-(3-butoxy-3-phenylazetidin-1-yl)-1-(4-met...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323207(N-[(R)-1-(4-methoxybenzyl)-2-oxo-2-(3-pentyl-3-o-t...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323208(N-[(R)-2-[3-(4-fluorophenyl)-3-pentylazetidin-1-yl...)
Affinity DataEC50:  250nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323209(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  8.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323210(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  8.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323211(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  120nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323212(N-{(R)-1-(4-methoxybenzyl)-2-[3-(2-methoxyphenyl)-...)
Affinity DataEC50:  60nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323213(N-[(R)-2-[3-(2-fluorophenyl)-3-pentylazetidin-1-yl...)
Affinity DataEC50:  30nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323214(N-[(R)-2-[3-(2-chlorophenyl)-3-pentylazetidin-1-yl...)
Affinity DataEC50:  30nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323215(N-[(R)-1-(4-chlorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Affinity DataEC50:  2.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323216(N-[(R)-1-(4-fluorobenzyl)-2-oxo-2-(3-pentyl-3-phen...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323217(N-[(R)-1-benzyl-2-oxo-2-(3-pentyl-3-phenylazetidin...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323218(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  4.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323219(N-[(R)-2-[3-(2,4-difluorophenyl)-3-pentylazetidin-...)
Affinity DataEC50:  15nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323220(N-[(R)-2-oxo-2-(3-pentyl-3-phenylazetidin-1-yl)-1-...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323221(N-[(R)-2-oxo-2-(3-pentyl-3-phenylazetidin-1-yl)-1-...)
Affinity DataEC50:  1.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

Displayed 1 to 50 (of 1827 total ) | Next | Last >>
Jump to: